Skip to content
Menu

NewAmsterdam Pharma Company N.V. NAMS

Full chart Compare
Set alert

Price alert · NAMS

All alert types
19.51 USD -0.23 (-1.17%)

Regular-session close

18.90 -0.61 -3.12%

After hours · Nov 19, 5:01 PM ET

19.30 Day range 20.36
17.90 52-week range 42.21
YTD
-44.38%
1 year
-49.48%

5D -0.28 (-1.41%)

1919.502020.50FriMonTueWedThu19.64
Market cap
2.34B
Revenue (ttm)
25.94M
EPS (ttm)
-1.69
Shares out
119.93M
Forward P/E
-9.40
YTD return
-44.38%
1-year return
-49.48%
50-day average
21.22
200-day average
28.97
Enterprise value
1.74B
Volume
1.98M
Avg volume
1.63M
Open
20.14
Previous close
19.74
Day's range
19.30 – 20.36
52-week range
17.90 – 42.21
Beta
0.14
Analysts
Strong Buy
Price target
50.73 (+160.0%)
Earnings date
Feb 17, 2027

Key statistics

Price / sales
90.21
Price / book
3.71
Revenue growth
5406.90%
Free cash flow
-98.63M
Total cash
628.24M
Total debt
76.00K
Return on equity
-30.16%
Short % of float
11.72%

Fundamental scorecard

4 of 25 checks passed on NAMS’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NAMS Revenue — quarterly 19.16M
NAMS Net income — quarterly -17.39M
NAMS EPS — quarterly -0.14

Earnings

NAMS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 17, 2027Dec 30, 2026-0.44———
Nov 4, 2026Sep 30, 2026-0.47179-0.14+0.33+70.33%
Aug 5, 2026Jun 30, 2026-0.48191-0.52-0.04-7.90%
May 7, 2026Mar 31, 2026-0.46-0.40+0.06+13.04%
Feb 18, 2026Dec 31, 2025-0.4342-0.63-0.20-45.09%
Nov 5, 2025Sep 30, 2025-0.38-0.61-0.23-60.53%

Upgrades / downgrades

NAMS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026Cantor FitzgeraldmainOverweightOverweight
Nov 5, 2026NeedhammainBuyBuy
Oct 5, 2026RBC CapitalmainOutperformOutperform
Sep 8, 2026HC Wainwright & Co.reitBuyBuy
Aug 6, 2026RBC CapitalmainOutperformOutperform
Jun 30, 2026RBC CapitalmainOutperformOutperform

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sector
Healthcare
Industry
Biotechnology
Country
Netherlands

News

Your note

Sign in to keep a note on NAMS — it syncs with the Stock Master app.

Insider holders

NAMS insider holders
InsiderRelationLatest transactionDateShares held
AUDET JULIETTE BERANGEREOfficerStock Award(Grant)Jan 6, 202515,104
DAVIDSON MICHAEL HChief Executive OfficerPurchaseSep 13, 20261,078,640
FORGROWTH NAP B.V.Beneficial Owner of more than 10% of a Class of SecuritySaleDec 29, 20240
JONES WILLIAM A JROfficerStock Award(Grant)Jan 6, 202543,000
KASTELEIN JOHANNES JACOB PIETEROfficer and DirectorSaleAug 23, 20260
KLING DOUGLAS FChief Operating OfficerSaleJul 15, 202544,000

Institution ownership

NAMS institution ownership
Holder% heldSharesValueReported
Frazier Life Sciences Management, L.P. 15.83%18,988,902370.47MSep 29, 2026
Capital World Investors10.74%12,881,484251.32MSep 29, 2026
FMR, LLC10.10%12,116,744236.40MSep 29, 2026
RA Capital Management, L.P.7.96%9,550,191186.32MSep 29, 2026
Janus Henderson Group Ltd.7.48%8,972,293175.05MSep 29, 2026
FCPM III Services B.V.7.08%8,490,353165.65MSep 29, 2026

Fund ownership

NAMS fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc7.97%9,562,970186.57MSep 29, 2026
Fidelity Contrafund1.92%2,304,82644.97MSep 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.84%2,204,73843.01MSep 29, 2026
New Economy Fund1.04%1,246,09324.31MSep 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund0.97%1,164,95122.73MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio0.85%1,020,00019.90MSep 29, 2026